Fig. 1From: Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastomaExpression of PD-L1 after staining of slides by microscopy, comparison of PD-L1-positive and PD-L1-negative tissue specimensBack to article page